Suprachoroidal Triamcinolone Acetonide Injection to Treat Macular Edema: A Review

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Chorioretinal diseases pose significant challenges to vision.
• Effective and safe treatment options are continuously sought.
• Triamcinolone acetonide is a corticosteroid with anti-inflammatory properties.

Purpose of the Study:

• To review the literature on the efficacy and safety of suprachoroidal triamcinolone acetonide.
• To assess its use in various chorioretinal conditions.
• To identify potential adverse events associated with this treatment.

Main Methods:

• Systematic literature review of clinical studies.
• Analysis of 17 clinical trials involving suprachoroidal triamcinolone acetonide.
• Inclusion of studies on diabetic macular edema, retinal vein occlusion, noninfectious uveitis, and post-cataract surgery cystoid macular edema.

Main Results:

• Suprachoroidal triamcinolone acetonide demonstrated effectiveness in reducing macular thickness.
• Improvements in visual acuity (VA) were observed across treated conditions.
• Commonly reported adverse events included eye pain, cataract formation, and elevated intraocular pressure.

Conclusions:

• Suprachoroidal triamcinolone acetonide exhibits a satisfactory safety and efficacy profile for chorioretinal diseases.
• Evidence is strongest for noninfectious uveitis, supported by three adequately powered trials.
• Larger sample size studies are recommended to definitively establish its therapeutic role in retinal diseases.